InMed Pharmaceuticals SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 5, 2026, 6:04 a.m. ETView on SEC.gov
Amendments to articles or bylaws; fiscal year change · Submission of matters to a vote of security holders · Other events · Financial statements and exhibits
AI summary, unreviewedInMed Pharmaceuticals (to be renamed Mentari Therapeutics) completes 1-for-10 reverse split and shareholder approval of Mentari merger; shares outstanding fall to about 549,374
8-KNov. 5, 2026, 8:08 a.m. ETView on SEC.gov Our explainer
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedInMed Pharmaceuticals Shareholders Approve Merger-Related Proposals, Name Change to Mentari Therapeutics, and 1-for-10 Share Consolidation
8-KNov. 3, 2026, 4:47 p.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedInMed Pharmaceuticals Reports Q1 Fiscal 2027 Net Loss of $2.3 Million; Cash Falls to $1.0 Million Amid Pending Mentari Merger and Nasdaq Equity Deficiency
8-KSept. 18, 2026, 5:11 p.m. ETView on SEC.gov
Delisting notice / failure to meet listing standard · Other events · Financial statements and exhibits